About Us
Part of the global pharmaceutical UBI Group, UBI Pharma consolidates the Group’s established values and builds a strong foundation of technology and production in the manufacture of pharmaceuticals, providing world-class pharmaceutical quality products. We develop innovative products such as non-monoclonal antibodies, novel small molecule drugs, and specialty injectables.
Major Milestones
Learn more about our corporate governance, financial and investor information from the material information announcements posted on the Market Observation Post System.
Milestones in 2023
2023
2022
Milestones in 2022
Milestones in 2021
2021
2020
Milestones in 2020
September 22
Announcement that the company's product Desmopressin Acetate Injection ANDA has been approved by US FDA.
May 28
UBI Pharma passed the routine inspection of Good Manufacturing Practice (GMP) by Taiwan Ministry of Health and Welfare(TFDA).
April 14
Announcement that the company's own product Olanzapine for Injection 10 mg (Olanzapine for Injection 10 mg) ANDA has been approved by TFDA .
February 17
Announcement Desmopressin Acetate Injection ANDA has been approved by US FDA.
Milestones in 2019
2019
2018
Milestones in 2018
The novel B-Raf targeted anticancer drug UB-941 received the 15th National Innovation Award.
Ms. Hsiu-Lien Chang and Mr. Chei-Hsiang Chen served as the chairman and general manager of UBI Pharma.
UBI Pharma was issued the EU patent certificate for the Recombinant Protein technology platform.
UBI Pharma received the 15th Taiwan Golden Root Award.
March 3
In partnership with the U.S. General Electric Company, UBI Pharma began the construction of a production facility for multifunctional protein drugs in Yangzhou, China.
Milestones in 2017
Production of sterile products at the Hsinchu Plant passed the GMP inspection by the Japan PMDA, and received the Accreditation Certificate of Foreign Drug Manufacturer issued by the Ministry of Health, Labor and Welfare, Japan.
2017
2016
Milestones in 2016
The President commended UBI Pharma’s achievements in innovative developments and outstanding contributions to medical science.
UBI Pharma was recognized as one of the “Top 10 Outstanding Companies of the Year” and received the Innovative Design of the Year award at the 13th Golden Torch Awards.
UBI Pharma’s innovative erythropoietin UB-852 and interferon α8 UB-551 received the 13th National Brand Yushan Award, including the National First Prize for Best Product.
Obtained the U.S. FDA IND approval for the novel anticancer drug B-Raf targeted kinase inhibitor UB-941.
UBI Pharma’s B-Raf targeted kinase inhibitor UB-941 received the “Innovation of the Year” award at the 2016 Taiwan BIO Awards.
Received a grant from the Technology Development Programs of the Ministry of Economic Affairs for the phase III clinical trial of the human erythropoietin UB-851
Obtained the license from the Development Center for Biotechnology for the anticancer drug UB-941 B-Raf targeted kinase inhibitor.
UBI Pharma was listed in the Emerging Board of Taipei Exchange Market under the ticker of “6562”.
Milestones in 2015
Vice President of the R&D Center, Dr. Wen-Chun Peng was commended by the President on behalf of UBI Pharma for the company’s outstanding achievements in the development of new drugs and brand management.
Obtained the Certificate for Good Manufacturing Practice (PIC/S GMP certificate).
January 27
Formosa Biomedical Technology Co., Ltd. joined and became an important strategic partner.
Formosa Biomedical Technology Co., Ltd. joined and became an important strategic partner.
January 23
UBI Pharma obtained factory registration.
UBI Pharma obtained factory registration.
2015
2014
Milestones in 2014
UBI Pharma was spin off and established from the non-monoclonal antibody drug and chemical pharmaceutical business from United Biomedical, Inc., Asia.
UBI Pharma Inc.
No.45, Guangfu N. Rd., Hukou Township, Hsinchu County 303036, Taiwan (R.O.C.)
- Tel：+886-3-5977676
- Fax：+886-3-5981173